SLC5A2 and type 2 diabetes mellitus: Six oral SGLT2 inhibitors are currently approved for the treatment of T2DM by the FDA together with the European Medicines Agency (EMA): canagliflozin (CANA), empagliflozin (EMPA), dapagliflozin (DAPA), ertugliflozin (ERTU), bexagliflozin, and sotagliflozin [15].